MTVA logo

MTVA MetaVia Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.01
-0.06 (-5.61%)

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated …

Market Cap: $6.81Mwww.metaviatx.com

Price

No data yet.

Social Signal Score

38
5d
—
30d
40
6 mentions
—
60d
36
7 mentions
—
90d
37
8 mentions
—
news: 8

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-8.89
$-8.89–$-8.89
2 analysts
FY2026
$-2.70
$-3.29–$-2.11
1 analysts
FY2027
$-2.23
$-3.17–$-1.29
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Hyung Heon Kim
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
0.96
Country
US
Piotroski score
0 / 9 (Weak)
Altman Z-score
-28.41
www.metaviatx.com